Sino Biopharmaceutical Ltd
Company Profile
Business description
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Contact
1 Harbour Road
Unit 09, 41st Floor, Office Tower, Room 4109
Convention Plaza
Wanchai
Hong Kong
HKGT: +852 28029886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
23,056
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 40.60 | -0.44% |
| CAC 40 | 8,184.16 | 80.32 | 0.99% |
| DAX 40 | 24,194.35 | 403.70 | 1.70% |
| Dow JONES (US) | 48,717.02 | 215.75 | 0.44% |
| FTSE 100 | 10,573.18 | 89.05 | 0.85% |
| HKSE | 25,249.48 | 518.60 | -2.01% |
| NASDAQ | 22,769.63 | 252.94 | 1.12% |
| Nikkei 225 | 54,245.54 | 2,033.51 | -3.61% |
| NZX 50 Index | 13,531.12 | 125.53 | -0.92% |
| S&P 500 | 6,860.17 | 43.54 | 0.64% |
| S&P/ASX 200 | 8,901.20 | 35.80 | -0.40% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |